Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	**2.8 Western blotting**	

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	**2.1 Clinical samples and cell lines**	
Primary cultures: Provide species, strain, sex of origin, genetic modification status.	**2.1 Clinical samples and cell lines**	

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID	This work was not carried out in this study.	N/A
Animal observed in or captured from the field: Provide species, sex and age where possible	This work was not carried out in this study.	N/A
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID	This work was not carried out in this study.	N/A

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)	This work was not carried out in this study.	N/A
Microbes: provide species and strain, unique accession number if available, and source	This work was not carried out in this study.	N/A

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	**2.1 Clinical samples and cell lines**	
Provide statement confirming informed consent obtained from study participants.	**2.1 Clinical samples and cell lines**	
Report on age and sex for all study participants.	Table1: Correlation between APOC1P1 expression and clinicopathologic features of HCC patients.	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.	This work was not carried out in this study.	N/A

Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.	This work was not carried out in this study.	N/A

Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done**, or** if they were not carried out.		
Sample size determination	**2 Methods**	
Randomisation	This work was not carried out in this study.	N/A
Blinding	This work was not carried out in this study.	N/A
Inclusion/exclusion criteria	**2 Methods**	

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	This work was not carried out in this study.	N/A
Define whether data describe technical or biological replicates	This work was not carried out in this study.	N/A

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	This work was not carried out in this study.	N/A
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	This work was not carried out in this study.	N/A
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	**2.1 Clinical samples and cell lines**	

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	This work was not carried out in this study.	N/A

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	This work was not carried out in this study.	N/A

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	**2.9 Statistical analysis**	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	**2.6 Bioinformation analysis**	
If data are publicly available, provide accession number in repository or DOI or URL.	**2.6 Bioinformation analysis**	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	**2.6 Bioinformation analysis**	

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		N/A
State whether the code or software is available.	This work was not carried out in this study	N/A
If code is publicly available, provide accession number in repository, or DOI or URL.	This work was not carried out in this study	N/A

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article Information: https://dx.doi.org/10.21037/tcr-23-2189